25mg Quetiapine

1. Classification and Chemical Overview

Quetiapine (as quetiapine fumarate) is a dibenzothiazepine derivative categorised pharmacologically as a second-generation (atypical) antipsychotic. Under the Anatomical Therapeutic Chemical (ATC) classification system, it is indexed under N05AH04.

Chemically designated as 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethoxy]ethanol fumarate, quetiapine exhibits moderate solubility in aqueous media. In United Kingdom clinical practice, quetiapine 25 mg is routinely formulated as film-coated, immediate-release oral tablets. In accordance with the Human Medicines Regulations 2012, quetiapine is classified as a Prescription Only Medicine (POM).

2. Mechanism of Action and Pharmacodynamics

Quetiapine and its primary human plasma active metabolite, norquetiapine, interact with a broad spectrum of neurotransmitter receptors. Quetiapine exhibits antagonist activity at central serotonin 5-HT2​ receptors and dopamine D1​ and D2​ receptors. Antagonism at 5-HT2​ receptors relative to D2​ receptors is higher, which contributes to its atypical clinical profile and reduced propensity for extrapyramidal side effects (EPS) compared to typical antipsychotics.

Norquetiapine displays high affinity as an inhibitor of the norepinephrine transporter (NET) and acts as a partial agonist at serotonin 5-HT1A​ receptors, contributing to antidepressant efficacy. Both quetiapine and norquetiapine exhibit high affinity for histamine H1​ receptors and alpha$_1$-adrenergic receptors, explaining the prominent sedative and orthostatic hypotensive effects observed at low starting doses (such as 25 mg). Conversely, affinity for muscarinic M1 receptors is low-to-moderate, primarily driven by norquetiapine.

Dose-response dynamics indicate that lower daily doses (25 mg to 50 mg) yield predominantly H1​ and alpha$_1$-adrenergic blockade, whereas higher therapeutic doses (300 mg to 800 mg daily) are required to achieve sufficient D2​ receptor occupancy ($>60\%$) for robust antipsychotic action.

3. Approved UK Clinical Indications and Therapeutic Scope

Licensing by the Medicines and Healthcare products Regulatory Agency (MHRA) for immediate-release quetiapine includes:

• Bipolar Disorder: Treatment of moderate-to-severe manic episodes associated with bipolar disorder; treatment of major depressive episodes in bipolar disorder; prevention of relapse in manic or depressed episodes in patients with bipolar disorder who previously responded to quetiapine.

• Schizophrenia: Treatment of acute and chronic schizophrenia.

Note on 25 mg Dosage Strength: The 25 mg immediate-release formulation is primarily utilized during mandatory initial dose-titration schedules for the licensed indications above to mitigate the risk of orthostatic hypotension and severe sedation. It is also used in lower-dose regimes in elderly or hepatically impaired patients.

NICE & BNF Guidance Context: Although off-label use for insomnia or general anxiety is not supported by MHRA licensing due to unfavorable risk-benefit ratios regarding metabolic adverse effects, low-dose quetiapine is sometimes encountered in secondary care specialist pathways as an off-label adjunctive agent for severe, treatment-resistant anxiety or behavioral and psychological symptoms of dementia (BPSD) where non-pharmacological interventions have failed and cerebrovascular risks have been evaluated.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Quetiapine is rapidly and well absorbed following oral administration. Peak plasma concentration (Tmax​) is achieved approximately 1.5 hours post-dose for immediate-release formulations. Co-administration with food modestly increases peak concentration (Cmax​) and area under the curve (AUC), but immediate-release tablets may be administered with or without food. Absolute oral bioavailability is estimated at approximately 9% to 11% due to extensive first-pass hepatic metabolism.

• Distribution: Quetiapine is widely distributed throughout body tissues, with an apparent volume of distribution (Vd​) of approximately $10\pm 4\text{ L/kg}$. Plasma protein binding is approximately 83% at therapeutic concentrations. Quetiapine crosses the blood-brain barrier as well as the placental barrier.

• Biotransformation: Quetiapine undergoes extensive hepatic biotransformation via Phase I oxidative pathways. Cytochrome P450 3A4 (CYP3A4) is the primary enzyme responsible for the metabolism of quetiapine to its main metabolite, quetiapine sulfoxide (inactive), and to norquetiapine (active). Phase II conjugation pathways (glucuronidation) are also involved.

• Elimination: Elimination is predominantly via hepatic metabolism. Approximately 73% of radiolabelled drug is excreted in urine and 21% in faeces, with less than 5% excreted as unchanged drug. Systemic clearance is approximately 1 to 1.5 L/min. The mean terminal elimination half-life (t1/2​) of quetiapine is approximately 6 to 7 hours; the half-life of norquetiapine is approximately 12 hours.

5. Physiological Effects and Adverse Event Spectrum

Quetiapine alters central nervous system neurotransmission, resulting in sedating, anxiolytic, and antipsychotic effects alongside systemic cardiovascular and metabolic modifications.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Somnolence, dizziness, headache, dry mouth, withdrawal symptoms (upon abrupt cessation), increased serum triglyceride levels, increased total cholesterol, decreased HDL cholesterol, weight gain, decreased haemoglobin.

• Common ($\ge 1/100$ to $<1/10$): Leukopenia, neutropenia, eosinophilia, hyperprolactinaemia, increased appetite, abnormal dreams and nightmares, extrapyramidal symptoms (dysarthria, dystonia, akathisia), orthostatic hypotension, tachycardia, rhinitis, constipation, dyspepsia, elevated serum transaminases (ALT, AST), peripheral oedema, asthenia.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Thrombocytopenia, hypersensitivity reactions (including anaphylaxis), hyponatremia, dysphasia, tardive dyskinesia, syncope, QT-interval prolongation, bradycardia, seizures, urinary retention, sexual dysfunction.

• Rare ($\ge 1/10,000$ to $<1/1,000$): Agranulocytosis, neuroleptic malignant syndrome (NMS), venous thromboembolism, pancreatitis, jaundice, hepatitis, priapism, rhabdomyolysis, metabolic syndrome.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindications

• Hypersensitivity to quetiapine or any formulation excipients.

• Concomitant administration with potent Cytochrome P450 3A4 inhibitors (e.g., azole antifungals such as ketoconazole, HIV protease inhibitors, erythromycin, clarithromycin, and nefazodone).

Key Drug Interactions

• CYP3A4 Inhibitors: Substantially increase quetiapine plasma concentrations; co-administration is strictly contraindicated.

• CYP3A4 Inducers: Agents such as carbamazepine, phenytoin, rifampicin, and St John’s Wort significantly enhance quetiapine clearance, reducing efficacy. Dose adjustment may be required if an inducer is started or stopped.

• Centrally Acting Agents & Alcohol: Enhanced CNS depression and sedation when combined with benzodiazepines, opioids, or alcohol.

• Antihypertensives: Potential enhancement of hypotensive effects due to alpha$_1$-adrenergic blockade.

• QT-Prolonging Drugs: Caution is required when co-prescribed with drugs known to cause electrolyte imbalance or prolong the QT interval (e.g., class IA/III antiarrhythmics, macrolide antibiotics, tricyclic antidepressants).

Clinical Precautions and Monitoring

• Cardiovascular Risk: Use with caution in patients with known cardiovascular disease, cerebrovascular disease, or conditions predisposing to hypotension.

• Suicidality: Patients with major depressive episodes or bipolar disorder must be closely monitored for clinical worsening and suicidal ideation, particularly during initial titration.

• Elderly Patients with Dementia: Atypical antipsychotics are associated with an increased risk of cerebrovascular adverse events and all-cause mortality in elderly patients with dementia-related psychosis.

• Metabolic Monitoring: Baseline and periodic monitoring of body weight, blood glucose (HbA1c), and lipid profiles is recommended. Baseline full blood counts and liver function tests should be conducted and monitored periodically thereafter.